The Sanger Institute is a nonprofit research institute founded in 1963 by Nobel laureate Ernest S. Sanger.
The Sledge Institute is also a non-profit research institute.
Salk has a long history of advancing scientific and technological progress, and his institute is known for its collaborations with a wide range of research institutions around the world.
Salk and the Sledge institute collaborated on an important project in 2009 called the Salk Protocol, which was designed to build a “network” for developing vaccines that would prevent the spread of diseases caused by HIV and other viral pathogens.
The idea was to establish a protocol that would allow scientists and medical researchers to develop vaccines that were more likely to protect against those diseases.
The process would allow for a rapid, cost-effective and efficient way to protect people against these diseases.
The Salk protocol developed through the Sanger-Sledge Institute Project has been instrumental in developing vaccines for HIV, hepatitis B, and other diseases.
In 2014, Salk received a Nobel Prize in Medicine for his work on this project.
In a statement to Wired, Sanger said that the Salker Institute was the only group of scientists that would have a direct link with the Sake Foundation.
Sanger was also very interested in what was going on in the world of science at the time.
The fact that a group of people had come together, to create a scientific project and to make it happen, was really important, he said.
“I’m interested in the things that we could do together, and I think that’s where our collaboration really began,” Sanger told Wired.
“It’s very rare to find an institute that does a research project of this size in any kind of way and with the support of the Sangean Foundation,” Sangea said.
The foundation has been involved in several research projects, including one called the Interdisciplinary Scientific Research Project on HIV.
The first Salk project, which took place at Salk’s institute, was the Senge Vaccine.
The project, created in 1959, was a collaboration between scientists working on various aspects of the vaccine, and was a huge success.
Sake and Salk are both major players in vaccine research.
Sangeas vaccine was approved by the FDA in 1977.
Sake was involved in a series of vaccine projects in the 1970s and 1980s, including a vaccine developed in the late 1960s called the Human Vaccine Development Program.
Suke, the other Salk researcher, has worked on many other vaccines, including the polio vaccine and the herpes vaccine.
The work was funded by the National Institutes of Health.
Saku was involved with the HIV vaccine, which is known as the SV40 vaccine.
This vaccine was developed by Salk and his collaborators in the early 1970s, and has been shown to be safe.
Saku, who is also the former head of the National Institute of Allergy and Infectious Diseases, was instrumental in creating the first vaccine that protected people from HIV.